

119<sup>TH</sup> CONGRESS  
1<sup>ST</sup> SESSION

# H. R. 4570

To amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes.

---

## IN THE HOUSE OF REPRESENTATIVES

JULY 21, 2025

Mr. NEGUSE introduced the following bill; which was referred to the  
Committee on the Judiciary

---

## A BILL

To amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Interagency Patent  
5 Coordination and Improvement Act of 2025”.

1 **SEC. 2. FINDINGS.**

2 Congress finds the following:

3 (1) Decisions by the United States Patent and  
4 Trademark Office relating to patents may implicate,  
5 or have relevance to, information housed at or in-  
6 volving other Federal agencies.

7 (2) Entities submitting patent applications to  
8 the United States Patent and Trademark Office may  
9 also submit information to, or share information  
10 with, other Federal agencies, necessitating accuracy  
11 and consistency in those representations.

12 (3) Research has shown that patent examiners  
13 may benefit from additional information that is  
14 housed at, or is available to, Federal agencies other  
15 than the United States Patent and Trademark Of-  
16 fice in order to assess prior art and the state of  
17 science and technology.

18 (4) The Under Secretary of Commerce for In-  
19 tellectual Property and Director of the United States  
20 Patent and Trademark Office is encouraged to work  
21 with other Federal agencies.

22 **SEC. 3. REPORT BY UNITED STATES PATENT AND TRADE-**  
23 **MARK OFFICE.**

24 Not later than 4 years after the date of enactment  
25 of this Act, the Under Secretary of Commerce for Intellec-  
26 tual Property and Director of the United States Patent

1 and Trademark Office shall submit to the Committee on  
2 the Judiciary of the Senate and the Committee on the Ju-  
3 diciary of the House of Representatives a report that con-  
4 tains—

5 (1) a description of the frequency with which—

6 (A) information is provided by the Food  
7 and Drug Administration to the United States  
8 Patent and Trademark Office through the  
9 Interagency Task Force on Patents established  
10 under section 14 of title 35, United States  
11 Code, as added by section 4(a) of this Act, or  
12 under processes established by that Task Force;  
13 and

14 (B) the information described in subpara-  
15 graph (A) is used in patent examinations;

16 (2) an identification of which methods of pro-  
17 viding information, as described in paragraph  
18 (1)(A), and types of information so shared, are most  
19 useful to patent examiners;

20 (3) any recommendations for changes to be  
21 made by Congress to the mandate, funding, or oper-  
22 ations of the Task Force described in paragraph  
23 (1)(A); and

24 (4) an identification of other Federal agencies  
25 with which the Under Secretary of Commerce for In-

1 intellectual Property and Director of the United States  
2 Patent and Trademark Office should explore oppor-  
3 tunities for coordination that are similar to those  
4 undertaken with the Food and Drug Administration  
5 through the activities of the Task Force described in  
6 paragraph (1)(A).

7 **SEC. 4. INTERAGENCY TASK FORCE ON PATENTS.**

8 (a) IN GENERAL.—Chapter 1 of title 35, United  
9 States Code, is amended—

10 (1) in section 2(c), by adding at the end the fol-  
11 lowing:

12 “(6)(A) In exercising the Director’s powers and du-  
13 ties under this section relating to patents, and decisions  
14 or actions involving patents, for human drugs and biologi-  
15 cal products, the Director shall, through the Interagency  
16 Task Force on Patents established under section 14, con-  
17 sult with the Commissioner of Food and Drugs in the  
18 manner described in that section.

19 “(B) For purposes of subparagraph (A), the term  
20 ‘decisions or actions involving patents’ means decisions or  
21 actions taken with respect to patents under this title.”;  
22 and

23 (2) by adding at the end the following:

1 **“§ 14. Interagency Task Force on Patents**

2       “(a) ESTABLISHMENT.—There is established an  
3 interagency task force, to be known as the Interagency  
4 Task Force on Patents (referred to in this section as the  
5 ‘task force’), to coordinate efforts between the Director  
6 and the Commissioner of Food and Drugs (referred to in  
7 this section as the ‘Commissioner’) regarding communica-  
8 tion about, evaluation of, and effective implementation of  
9 the activities of the Office and the Food and Drug Admin-  
10 istration with respect to patents, and decisions or actions  
11 involving patents (as defined in section 2(c)(6)(B)), for  
12 human drugs and biological products.

13       “(b) MEMORANDUM OF UNDERSTANDING.—The Di-  
14 rector and the Commissioner shall enter into a memo-  
15 randum of understanding, or update an existing memo-  
16 randum of understanding, for the purposes of imple-  
17 menting and carrying out the duties of the task force.

18       “(c) MEMBERSHIP.—The task force shall be com-  
19 prised of employees of the Office, who shall be appointed  
20 by the Director, and employees of the Food and Drug Ad-  
21 ministration, who shall be appointed by the Commissioner,  
22 who have appropriate expertise and decision-making au-  
23 thority regarding operational, administrative, technical,  
24 medical, pharmacological, clinical, and scientific matters  
25 to carry out the functions of the task force.

1       “(d) ACTIVITIES.—The task force shall carry out the  
2 following functions regarding interagency coordination to  
3 promote reciprocal access of information:

4           “(1) Sharing information on the general proc-  
5 esses of the Office and the Food and Drug Adminis-  
6 tration, what each such agency considers in its re-  
7 spective review of applications, and how each such  
8 agency evaluates those applications, which may be  
9 undertaken through routine and ongoing meetings,  
10 workshops, and training sessions.

11           “(2) Sharing information on new approvals of  
12 patents, human drugs and biological products, new  
13 technologies and prior art (as appropriate on a case-  
14 by-case basis), and scientific trends and develop-  
15 ments.

16           “(3) Establishing a process that requires—

17           “(A) the Director to request from the  
18 Commissioner (and the Commissioner to pro-  
19 vide to the Director, upon receiving such a re-  
20 quest)—

21           “(i) appropriate information for use  
22 by employees of the Office with responsi-  
23 bility to examine patent applications under  
24 section 131 (referred to in this section as  
25 ‘patent examiners’) regarding when certain

1 information relating to a human drug or  
2 biological product approval, which may in-  
3 clude updates to a label or newly approved  
4 indications, is made publicly available, in-  
5 cluding when such information is posted  
6 online; and

7 “(ii) appropriate access for patent ex-  
8 aminers to relevant sources of product ap-  
9 plication, approval, patent, and labeling in-  
10 formation or communications between the  
11 Food and Drug Administration and the  
12 human drug or biological product sponsors  
13 that may not currently be subject to public  
14 disclosure, as appropriate and only to the  
15 extent necessary for the Office to carry out  
16 the responsibilities of the Office, such as  
17 ensuring accurate representations and ac-  
18 cess to information on whether the claimed  
19 invention that would be the subject of the  
20 patent was on sale before the effective fil-  
21 ing date of the claimed invention, as de-  
22 scribed in section 102(a)(1); and

23 “(B) the Office to assist the Food and  
24 Drug Administration in its ministerial role of  
25 listing patents.

1           “(4) Establishing a process to ensure that, in  
2           appropriate circumstances, at the request of the Di-  
3           rector, the Commissioner shall consult with or other-  
4           wise furnish specific, available information to the Of-  
5           fice with respect to certain applications, responses,  
6           or affidavits after rejections in order to assist patent  
7           examiners in carrying out the duties of those patent  
8           examiners.

9           “(e) RULE OF CONSTRUCTION.—Nothing in sub-  
10          section (d)(3)(B) shall be construed as—

11           “(1) directing the Office to interfere with,  
12           delay, or supersede the ministerial function of the  
13           Food and Drug Administration of listing patents;

14           “(2) indicating the position of the Office re-  
15           garding the ability to assert a patent in infringement  
16           litigation; or

17           “(3) changing the ministerial function of the  
18           Food and Drug Administration of listing patents.

19           “(f) CONFIDENTIALITY.—

20           “(1) IN GENERAL.—With respect to any record  
21           or other information of the Food and Drug Adminis-  
22           tration or the Office that is confidential, either such  
23           agency may share any such information with the  
24           other agency in furtherance of the activities de-  
25           scribed in this section, which shall remain subject to

1 such protections as if the information were held by  
2 the Food and Drug Administration.

3 “(2) PROTOCOLS.—

4 “(A) IN GENERAL.—The task force shall  
5 establish appropriate protocols to safeguard  
6 confidentiality and prevent the inappropriate  
7 disclosure of information when sharing informa-  
8 tion between the Office and the Food and Drug  
9 Administration.

10 “(B) CONTENTS.—The protocols estab-  
11 lished under subparagraph (A) shall provide  
12 that—

13 “(i) before sharing any information  
14 described in paragraph (1), the sponsor of  
15 the human drug or biological product to  
16 which that information relates shall be pro-  
17 vided notice of that sharing by the applica-  
18 ble agency and with a period of 30 days to  
19 consult with the agency sharing that infor-  
20 mation; and

21 “(ii) the Director shall, in order to  
22 protect against the inadvertent disclosure  
23 of information, maintain any information  
24 shared with the Director by the Commis-  
25 sioner separate from pending patent appli-

1 cations and establish procedures for the  
2 identification of confidential information.

3 “(C) POTENTIAL REMEDIES.—In estab-  
4 lishing protocols under this paragraph, the task  
5 force shall identify appropriate remedies for any  
6 potential injury suffered when confidential in-  
7 formation is made available, including inadvert-  
8 ently, through the sharing of information de-  
9 scribed in this subsection.

10 “(3) RULE OF CONSTRUCTION.—Nothing in  
11 this subsection may be construed as superseding any  
12 other remedy available for the unauthorized dislo-  
13 sure of confidential information.”.

14 (b) TECHNICAL AND CONFORMING AMENDMENT.—  
15 The table of sections for chapter 1 of title 35, United  
16 States Code, is amended by adding at the end the fol-  
17 lowing:

“14. Interagency Task Force on Patents.”.

○